Chee Kong Choo - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 3, 2026
Chee Kong Choo has filed 3 SEC Form 4 filings across 1 company in the last 90 days - buying. Lifetime open-market purchases: $729K.
Profile
Chee Kong Choo serves as Director of CytoMed Therapeutics Ltd (GDTC). Choo has reported 3 insider filings with the SEC since 2026. The most recent filing was in July 2026.
| Role | Director, 10% Owner |
|---|---|
| Notability | 36/100 |
Board memberships
- CytoMed Therapeutics Ltd
Reported roles
- Director
Awards & honors
- Director at CytoMed Therapeutics Ltd (as of 2026-06-15)
Trading Pattern
InsiderAlpha's records for Chee Kong Choo go back to 2026: 3 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $146K (5 buys totaling $729K). The largest single buy on record is $150K of GDTC in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Chee Kong Choo has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director, 10% Owner at CytoMed Therapeutics Ltd (GDTC) - 3 filings, 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-25 | GDTC | CytoMed Therapeutics Ltd | P - Open-market purchase | 100.0K | $1.50 | $150K |
| 2026-07-25 | GDTC | CytoMed Therapeutics Ltd | P - Open-market purchase | 100.0K | $1.50 | $150K |
| 2026-07-24 | GDTC | CytoMed Therapeutics Ltd | P - Open-market purchase | 100.0K | $1.50 | $150K |
| 2026-07-24 | GDTC | CytoMed Therapeutics Ltd | P - Open-market purchase | 100.0K | $1.50 | $150K |
| 2026-06-15 | GDTC | CytoMed Therapeutics Ltd | P - Open-market purchase | 112.0K | $1.15 | $129K |
Companies - Last 90 Days
- CytoMed Therapeutics Ltd (GDTC) - 3 filings, last 2026-07-25
Most Active Insiders Right Now
Chee Kong Choo has no recent co-filers at the same companies, so here are the insiders with the largest open-market activity across the market in the last 90 days.
- MetLife Investment Management, LLC - $1600000.00B of FINS open-market activity in the last 90 days
- Magnetar Financial LLC - $16357.48B of CRWV open-market activity in the last 90 days
- Marianne Okland - $18.46B of STNG open-market activity in the last 90 days
- VisionWave Holdings, Inc. - $14.13B of SVRE open-market activity in the last 90 days
- Vanessa Allen Sutherland - $7.44B of PSX open-market activity in the last 90 days
- AI Alpine (Luxembourg) S.a.r.l. - $2.69B of INIO open-market activity in the last 90 days
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Jorey Chernett
- John W. Childs
- Mahesh Choudhury
- Jonathan H. Cohen
- Ryan Cohen
- Charles K. Cohn
- Coliseum Capital Management, LLC
- Column Group IV GP, LP
Frequently Asked Questions
Who is Chee Kong Choo?
Chee Kong Choo serves as Director of CytoMed Therapeutics Ltd (GDTC). Choo has reported 3 insider filings with the SEC since 2026. The most recent filing was in July 2026.…
How many SEC Form 4 filings has Chee Kong Choo submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Chee Kong Choo been buying or selling stock?
Recorded transactions: 5 open-market purchases ($729K) and 0 open-market sales across all tracked filings.
Where can I see all of Chee Kong Choo's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Chee Kong Choo profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.